• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Induced Abortion Does Not Increase Rh Alloimmunization

October 4, 2023

Rh immunoglobulin routinely given to Rh-negative pregnant women during the second and third trimesters has reduced the maternal Rh sensitization rate from 10% to 0.2%.  Guidelines are variable for Rh immunoglobulin use during the first trimester, so many clinicians still test and treat pregnant women during this time.  To determine if Rh immunoglobin treatment is necessary for Rh-negative women undergoing first-trimester induced abortions, researchers in the U.S. enrolled 506 Rh-negative women (mean age, 27 years; 62% Black, 24% White) in their first trimester.  Fetal RBCs (fRBCs) were analyzed by flow cytometry both before and after the induced abortion.  None of the women had newly elevated fRBC counts above the sensitization threshold (125 fRBCs/5 million total RBCs), and only one woman had elevated counts after the abortion (0.2%; 95% C.I., 0% to 0.9%), suggesting that Rh testing and treatment are not necessary in the first trimester.  These data support the World Health Organization’s guideline to forgo Rh testing and treatment prior to abortions at less than 12 weeks gestation.

Reference:

Horvath S, Huang ZY, Koelper NC, Martinez C, Tsao PY, Zhao L, Goldberg AB, Hannum C, Putt ME, Luning Prak ET, Schreiber CA. Induced Abortion and the Risk of Rh Sensitization. JAMA. 2023 Sep 26;330(12):1167-1174.

 

Filed Under

  • News
  • Special Transfusion Situations

Recommended

  • mRNA-1273 Vaccine Safe and Induces anti-SARS-CoV-2 Immune Responses

  • Increase in New Blood Donors during the COVID-19 Pandemic

  • A New Drug for Patients with Thrombotic Thrombocytopenic Purpura

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley